Validation of the prevalence of RNF213 variants in patients with non-obstructive coronary artery disease (INOCA) for precision medicine and creation of a polygenic risk score model for the development of INOCA.

Validation of the prevalence of RNF213 variants in patients with non-obstructive coronary artery disease (INOCA) for precision medicine and creation of a polygenic risk score model for the development of INOCA. - Validation of the prevalence of RNF213 variants in patients with non-obstructive coronary artery disease (INOCA) for precision medicine and creation of a polygenic risk score model for the development of INOCA.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000053039

Enrollment

500

Registered

2023-12-11

Start date

2023-08-10

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary artery disease (including coronary spastic angina, and coronary microvascular dysfunction)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Non-obstructive coronary artery disease

Exclusion criteria

Exclusion criteria: Patients deemed inappropriate for participation in this study by the researcher Patients who declined the use of information for research

Design outcomes

Primary

Measure	Time frame
A polygenic risk score model for the development of INOCA	—

Secondary

Measure	Time frame
The prevalence of RNF213 variants, Prognosis, Therapeutic resistance, Rehospitalization, Vasoreactivity	—

Countries

Japan

Contacts

Public ContactTeruo Noguchi

National Cerebral and Cardiovascular Center Cardiovascular department

tnoguchi@ncvc.go.jp0661701070

Outcome results